

J Peter Donnelly

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6473184/j-peter-donnelly-publications-by-citations.pdf>
Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

221 papers	19,028 citations	56 h-index	135 g-index
239 ext. papers	21,372 ext. citations	7 avg, IF	6.08 L-index

#	Paper	IF	Citations
221	Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. <i>Clinical Infectious Diseases</i> , 2002 , 34, 7-14	11.6	3744
220	Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. <i>Clinical Infectious Diseases</i> , 2002 , 34, 7-14	11.6	2009
219	Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. <i>Cancer</i> , 2004 , 100, 1995-2025	6.4	1000
218	ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. <i>Clinical Microbiology and Infection</i> , 2012 , 18 Suppl 7, 19-37	9.5	774
217	2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. <i>European Journal of Cancer</i> , 2011 , 47, 8-32	7.5	727
216	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1367-1376	11.6	607
215	Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. <i>Lancet Infectious Diseases, The</i> , 2004 , 4, 349-57	25.5	400
214	EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. <i>Clinical Microbiology and Infection</i> , 2008 , 14, 398-405	9.5	348
213	Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. <i>Lancet Infectious Diseases, The</i> , 2009 , 9, 89-96	25.5	272
212	ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). <i>Clinical Microbiology and Infection</i> , 2012 , 18 Suppl 7, 53-67	9.5	241
211	ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. <i>Clinical Microbiology and Infection</i> , 2012 , 18 Suppl 7, 9-18	9.5	239
210	Aspergillus PCR: one step closer to standardization. <i>Journal of Clinical Microbiology</i> , 2010 , 48, 1231-40	9.7	224
209	International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. <i>Drug Resistance Updates</i> , 2015 , 21-22, 30-40	23.2	210
208	ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. <i>Clinical Microbiology and Infection</i> , 2012 , 18 Suppl 7, 38-52	9.5	206
207	In vitro activities of new and conventional antifungal agents against clinical Scodosporium isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 62-8	5.9	205
206	Early stop polymorphism in human DECTIN-1 is associated with increased candida colonization in hematopoietic stem cell transplant recipients. <i>Clinical Infectious Diseases</i> , 2009 , 49, 724-32	11.6	204
205	Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. <i>Bone Marrow Transplantation</i> , 2000 , 25, 1269-78	4.4	181

204	Comparison of NCCLS and 3-(4,5-dimethyl-2-Thiazyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. <i>Journal of Clinical Microbiology</i> , 2000 , 38, 2949-54	9.7	175
203	Specificity of a sandwich enzyme-linked immunosorbent assay for detecting <i>Aspergillus</i> galactomannan. <i>Journal of Clinical Microbiology</i> , 1997 , 35, 257-60	9.7	167
202	Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group. <i>Annals of Internal Medicine</i> , 1994 , 120, 834-44	8	161
201	Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. <i>Clinical Infectious Diseases</i> , 2013 , 57, 794-802	11.6	150
200	Optimization of the cutoff value for the <i>Aspergillus</i> double-sandwich enzyme immunoassay. <i>Clinical Infectious Diseases</i> , 2007 , 44, 1329-36	11.6	149
199	ECIL guidelines for preventing <i>Pneumocystis jirovecii</i> pneumonia in patients with haematological malignancies and stem cell transplant recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 2397-404	5.1	145
198	Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. <i>Annals of Pharmacotherapy</i> , 2005 , 39, 32-8	2.9	142
197	Colorimetric assay for antifungal susceptibility testing of <i>Aspergillus</i> species. <i>Journal of Clinical Microbiology</i> , 2001 , 39, 3402-8	9.7	142
196	Septicaemia caused by viridans streptococci in neutropenic patients with leukaemia. <i>Lancet, The</i> , 1983 , 2, 1452-4	4.0	138
195	ECIL guidelines for the diagnosis of <i>Pneumocystis jirovecii</i> pneumonia in patients with haematological malignancies and stem cell transplant recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 2386-96	5.1	132
194	<i>Aspergillus</i> Polymerase Chain Reaction: Systematic Review of Evidence for Clinical Use in Comparison With Antigen Testing. <i>Clinical Infectious Diseases</i> , 2015 , 61, 1293-303	11.6	130
193	Monitoring myeloablative therapy-induced small bowel toxicity by serum citrulline concentration: a comparison with sugar permeability tests. <i>Cancer</i> , 2005 , 103, 191-9	6.4	127
192	Evaluation of <i>Aspergillus</i> PCR protocols for testing serum specimens. <i>Journal of Clinical Microbiology</i> , 2011 , 49, 3842-8	9.7	126
191	Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). <i>Clinical Microbiology and Infection</i> , 2003 , 26, 147-54	9.5	116
190	European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 3221-3230	5.1	112
189	Prophylaxis and aspergillosis--has the principle been proven?. <i>New England Journal of Medicine</i> , 2007 , 356, 409-11	59.2	111
188	Therapeutic drug monitoring of voriconazole. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 403-11	3.2	107
187	Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 3599-604	5.9	104

186	Epidemiology and outcome of fungemia in a cancer Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031). <i>Clinical Infectious Diseases</i> , 2015 , 61, 324-31	11.6	96
185	Antimicrobial therapy to prevent or treat oral mucositis. <i>Lancet Infectious Diseases</i> , 2003 , 3, 405-12	25.5	95
184	Clinical Performance of Aspergillus PCR for Testing Serum and Plasma: a Study by the European Aspergillus PCR Initiative. <i>Journal of Clinical Microbiology</i> , 2015 , 53, 2832-7	9.7	89
183	Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts. <i>Clinical Microbiology and Infection</i> , 2003 , 9, i-viii	9.5	88
182	Citrulline: a potentially simple quantitative marker of intestinal epithelial damage following myeloablative therapy. <i>Bone Marrow Transplantation</i> , 2004 , 34, 193-6	4.4	86
181	Critical stages of extracting DNA from Aspergillus fumigatus in whole-blood specimens. <i>Journal of Clinical Microbiology</i> , 2010 , 48, 3753-5	9.7	81
180	Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. <i>Leukemia and Lymphoma</i> , 1993 , 11, 353-8	1.9	80
179	Voriconazole-a new therapeutic agent with an extended spectrum of antifungal activity. <i>Clinical Microbiology and Infection</i> , 2004 , 10 Suppl 1, 107-17	9.5	74
178	Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. The Meropenem Study Group of Leuven, London and Nijmegen. <i>Journal of Antimicrobial Chemotherapy</i> , 1995 , 36, 185-200	5.1	74
177	Role of the mycobiome in human acute graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 329-32	4.7	73
176	Intestinal damage determines the inflammatory response and early complications in patients receiving conditioning for a stem cell transplantation. <i>PLoS ONE</i> , 2010 , 5, e15156	3.7	71
175	Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11). <i>BMC Medicine</i> , 2009 , 7, 44	11.4	69
174	ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. <i>Clinical Microbiology and Infection</i> , 2012 , 18 Suppl 7, 1-8	9.5	67
173	Serial monitoring of Aspergillus antigen in the early diagnosis of invasive aspergillosis. Preliminary investigations with two examples. <i>Infection</i> , 1997 , 25, 86-9	5.8	66
172	In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 1998 , 42, 389-92	5.1	66
171	Infection prevention and control in health-care facilities in which hematopoietic cell transplant recipients are treated. <i>Bone Marrow Transplantation</i> , 2009 , 44, 495-507	4.4	64
170	ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. <i>Clinical Microbiology and Infection</i> , 2012 , 18 Suppl 7, 68-77	9.5	63
169	Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group. <i>Clinical Infectious Diseases</i> , 2015 , 60, 713-20	11.6	62

168	Inflammatory response to mucosal barrier injury after myeloablative therapy in allogeneic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2005 , 36, 703-7	4.4	57
167	Human platelets attenuate <i>Aspergillus</i> species via granule-dependent mechanisms. <i>Journal of Infectious Diseases</i> , 2008 , 198, 1243-6	7	56
166	Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 4096-102	5.9	56
165	A scheme for daily monitoring of oral mucositis in allogeneic BMT recipients. <i>Bone Marrow Transplantation</i> , 1992 , 9, 409-13	4.4	55
164	Febrile mucositis in haematopoietic SCT recipients. <i>Bone Marrow Transplantation</i> , 2009 , 43, 55-60	4.4	54
163	Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab. <i>Bone Marrow Transplantation</i> , 2013 , 48, 1465-71	4.4	53
162	NOD2 polymorphisms predict severe acute graft-versus-host and treatment-related mortality in T-cell-depleted haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2009 , 44, 243-8 ^{4.4}	4.4	53
161	Citrulline-based assessment score: first choice for measuring and monitoring intestinal failure after high-dose chemotherapy. <i>Annals of Oncology</i> , 2010 , 21, 1706-1711	10.3	52
160	Role of curcumin and the inhibition of NF-kappaB in the onset of chemotherapy-induced mucosal barrier injury. <i>Leukemia</i> , 2004 , 18, 276-84	10.7	52
159	European expert opinion on the management of invasive candidiasis in adults. <i>Clinical Microbiology and Infection</i> , 2011 , 17 Suppl 5, 1-12	9.5	51
158	Plasma citrulline measurement using UPLC tandem mass-spectrometry to determine small intestinal enterocyte pathology. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009 , 877, 387-92	3.2	51
157	Selective oral antimicrobial prophylaxis for the prevention of infection in acute leukaemia-ciprofloxacin versus co-trimoxazole plus colistin. The EORTC-Gnotobiotic Project Group. <i>European Journal of Cancer</i> , 1992 , 28A, 873-8	7.5	51
156	Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2359-2367	5.1	50
155	EUCAST technical note on anidulafungin. <i>Clinical Microbiology and Infection</i> , 2011 , 17, E18-20	9.5	50
154	Amphotericin B versus amphotericin B plus 5-flucytosine: poor results in the treatment of proven systemic mycoses in neutropenic patients. <i>Infection</i> , 1994 , 22, 81-5	5.8	50
153	Ceftazidime as monotherapy or combined with teicoplanin for initial empiric treatment of presumed bacteremia in febrile granulocytopenic patients. <i>Antimicrobial Agents and Chemotherapy</i> , 1991 , 35, 672-8	5.9	50
152	Breakpoints for susceptibility testing should not divide wild-type distributions of important target species. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 1628-9	5.9	48
151	Oral ketoconazole and amphotericin B for the prevention of yeast colonization in patients with acute leukaemia. <i>Journal of Hospital Infection</i> , 1984 , 5, 83-91	6.9	48

150	EUCAST Technical Note on voriconazole. <i>Clinical Microbiology and Infection</i> , 2008 , 14, 985-7	9.5	47
149	Prospective evaluation of gut mucosal barrier injury following various myeloablative regimens for haematopoietic stem cell transplant. <i>Bone Marrow Transplantation</i> , 2005 , 35, 707-11	4.4	47
148	Measuring mucosal damage induced by cytotoxic therapy. <i>Supportive Care in Cancer</i> , 2004 , 12, 227-33	3.9	46
147	Mucositis not neutropenia determines bacteremia among hematopoietic stem cell transplant recipients. <i>Transplant Infectious Disease</i> , 2014 , 16, 279-85	2.7	45
146	Two strategies for managing invasive aspergillosis: a decision analysis. <i>Clinical Infectious Diseases</i> , 1997 , 25, 1148-54	11.6	45
145	Procalcitonin does not discriminate infection from inflammation after allogeneic bone marrow transplantation. <i>Vaccine Journal</i> , 2000 , 7, 889-92		45
144	Statistical analyses of correlation between fluconazole MICs for <i>Candida</i> spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). <i>Journal of Clinical Microbiology</i> , 2007 , 45, 109-11	9.7	43
143	¹⁸ F-FDG PET/CT for diagnosing infectious complications in patients with severe neutropenia after intensive chemotherapy for haematological malignancy or stem cell transplantation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012 , 39, 120-8	8.8	40
142	Periodontal status and bacteremia with oral viridans streptococci and coagulase negative staphylococci in allogeneic hematopoietic stem cell transplantation recipients: a prospective observational study. <i>Supportive Care in Cancer</i> , 2013 , 21, 1621-7	3.9	40
141	Paradoxical increase in circulating <i>Aspergillus</i> antigen during treatment with caspofungin in a patient with pulmonary aspergillosis. <i>Clinical Infectious Diseases</i> , 2006 , 43, e23-5	11.6	40
140	Loss of enterocyte mass is accompanied by diminished turnover of enterocytes after myeloablative therapy in haematopoietic stem-cell transplant recipients. <i>Annals of Oncology</i> , 2009 , 20, 337-42	10.3	39
139	Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease. <i>Mycoses</i> , 2011 , 54, e449-55	5.2	38
138	Early identification of neutropenic patients at risk of grampositive bacteraemia and the impact of empirical administration of vancomycin. <i>European Journal of Cancer</i> , 1996 , 32A, 1332-9	7.5	38
137	Does the use in animals of antimicrobial agents, including glycopeptide antibiotics, influence the efficacy of antimicrobial therapy in humans?. <i>Journal of Antimicrobial Chemotherapy</i> , 1996 , 37, 389-92	5.1	38
136	Antifungal prophylaxis during neutropenia or allogeneic bone marrow transplantation: what is the state of the art? Ad HOC Working Group. <i>Chemotherapy</i> , 1992 , 38 Suppl 1, 43-9	3.2	38
135	Bacteraemia coincides with low citrulline concentrations after high-dose melphalan in autologous HSCT recipients. <i>Bone Marrow Transplantation</i> , 2008 , 42, 345-9	4.4	37
134	Failure of clindamycin to influence the course of severe oromucositis associated with streptococcal bacteraemia in allogeneic bone marrow transplant recipients. <i>Scandinavian Journal of Infectious Diseases</i> , 1993 , 25, 43-50		37
133	Duration of antifungal treatment and development of delayed complications in patients with candidaemia. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2003 , 22, 43-8	5.3	36

132	Analytical Comparison of In Vitro-Spiked Human Serum and Plasma for PCR-Based Detection of <i>Aspergillus fumigatus</i> DNA: a Study by the European <i>Aspergillus</i> PCR Initiative. <i>Journal of Clinical Microbiology</i> , 2015 , 53, 2838-45	9.7	34
131	Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 107-13	5.1	34
130	Safe living after hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2009 , 44, 509-19	4.4	34
129	A randomised, double-blinded, placebo-controlled, pilot study of parenteral glutamine for allogeneic stem cell transplant patients. <i>Supportive Care in Cancer</i> , 2005 , 13, 790-6	3.9	34
128	EUCAST breakpoints for antifungals. <i>Drug News and Perspectives</i> , 2010 , 23, 93-7		34
127	Software for dosage individualization of voriconazole for immunocompromised patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 1888-94	5.9	33
126	Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?. <i>British Journal of Haematology</i> , 2011 , 153, 681-97	4.5	33
125	The incidence of acute graft-versus-host disease increases with <i>Candida</i> colonization depending the dectin-1 gene status. <i>Clinical Immunology</i> , 2010 , 136, 302-6	9	33
124	Bacterial complications of transplantation: diagnosis and treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 1995 , 36 Suppl B, 59-72	5.1	33
123	Impaired gut function as risk factor for invasive candidiasis in neutropenic patients. <i>British Journal of Haematology</i> , 2002 , 117, 259-64	4.5	32
122	An open study on the safety and efficacy of fluconazole in the treatment of disseminated <i>Candida</i> infections in patients treated for hematological malignancy. <i>Annals of Hematology</i> , 1995 , 70, 83-7	3	31
121	Diagnosis of aspergillosis by PCR: Clinical considerations and technical tips. <i>Medical Mycology</i> , 2018 , 56, 60-72	3.9	30
120	Ceftazidime as first-line therapy for fever in acute leukaemia. <i>Journal of Infection</i> , 1985 , 11, 205-15	18.9	30
119	Reliability of clinical research on invasive fungal infections: a systematic review of the literature. <i>Medical Mycology</i> , 2001 , 39, 35-40	3.9	29
118	Serum C-reactive protein levels in the management of infection in acute leukaemia. <i>European Journal of Cancer & Clinical Oncology</i> , 1984 , 20, 319-25		29
117	Value of <i>Candida</i> serum markers in patients with invasive candidiasis after myeloablative chemotherapy. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009 , 64, 408-15	2.9	28
116	Citrulline and albumin as biomarkers for gastrointestinal mucositis in recipients of hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2013 , 48, 977-81	4.4	27
115	Empirical therapy of febrile neutropenic patients with mucositis: challenge of risk-based therapy. <i>Clinical Microbiology and Infection</i> , 2001 , 7 Suppl 4, 47-52	9.5	27

114	Primary hepatic invasive aspergillosis with progression after rituximab therapy for a post transplantation lymphoproliferative disorder. <i>Annals of Hematology</i> , 2006 , 85, 621-3	3	26
113	Selective decontamination of the digestive tract and its role in antimicrobial prophylaxis. <i>Journal of Antimicrobial Chemotherapy</i> , 1993 , 31, 813-29	5.1	26
112	Circulating Candida-specific anti-mannan antibodies precede invasive candidiasis in patients undergoing myelo-ablative chemotherapy. <i>Clinical Microbiology and Infection</i> , 2009 , 15, 380-6	9.5	25
111	Bacteremia due to oral viridans streptococci in neutropenic patients with cancer: cytostatics are a more important risk factor than antibacterial prophylaxis. <i>Clinical Infectious Diseases</i> , 1995 , 20, 469-70	11.6	25
110	Combination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 179-82	4.7	24
109	The antimicrobial effect of Isegran HCl oral solution in patients receiving stomatotoxic chemotherapy: analysis from a multicenter, double-blind, placebo-controlled, randomized, phase III clinical trial. <i>Journal of Oral Pathology and Medicine</i> , 2012 , 41, 229-34	3.3	24
108	Options and limitations of long-term oral ciprofloxacin as antibacterial prophylaxis in allogeneic bone marrow transplant recipients. <i>Bone Marrow Transplantation</i> , 1990 , 5, 179-82	4.4	23
107	How to manage lung infiltrates in adults suffering from haematological malignancies outside allogeneic haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2016 , 173, 179-89	4.5	22
106	Development and evaluation of a calibrator material for nucleic acid-based assays for diagnosing aspergillosis. <i>Journal of Clinical Microbiology</i> , 2013 , 51, 2403-5	9.7	21
105	Prospects for the early diagnosis of invasive aspergillosis in the immunocompromised patient. <i>Reviews in Medical Microbiology</i> , 1996 , 7, 105-114	1.1	21
104	Teicoplanin as modification of initial empirical therapy in febrile granulocytopenic patients. <i>Journal of Antimicrobial Chemotherapy</i> , 1990 , 25, 985-93	5.1	21
103	Performance of the new Platelia Candida Plus assays for the diagnosis of invasive Candida infection in patients undergoing myeloablative therapy. <i>Medical Mycology</i> , 2011 , 49, 848-55	3.9	20
102	Potential sites of infection that develop in febrile neutropenic patients. <i>Leukemia and Lymphoma</i> , 1993 , 10, 461-7	1.9	20
101	Options and limitations of teicoplanin in febrile granulocytopenic patients. <i>British Journal of Haematology</i> , 1990 , 76 Suppl 2, 1-5	4.5	20
100	Epidemiology of invasive aspergillosis and triazole-resistant <i>Aspergillus fumigatus</i> in patients with haematological malignancies: a single-centre retrospective cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 1389-1394	5.1	19
99	Determining the analytical specificity of PCR-based assays for the diagnosis of IA: What is <i>Aspergillus</i> ?. <i>Medical Mycology</i> , 2017 , 55, 402-413	3.9	19
98	An elevated pro-inflammatory cytokine response is linked to development of amphotericin B-induced nephrotoxicity. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 1655-9	5.1	19
97	A scoring system for the assessment of oral mucositis in daily nursing practice. <i>European Journal of Cancer Care</i> , 2006 , 15, 228-34	2.4	19

96	Cyclosporine short infusion and C2 monitoring in haematopoietic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2006 , 38, 521-5	4.4	19
95	Can anything be done about oral mucositis?. <i>Annals of Oncology</i> , 2003 , 14, 505-7	10.3	19
94	Pre-emptive administration of corticosteroids prevents the development of ARDS associated with <i>Streptococcus mitis</i> bacteremia following chemotherapy with high-dose cytarabine. <i>Annals of Hematology</i> , 1994 , 69, 69-71	3	19
93	A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1166-74	5.1	18
92	Improved detection of circulating <i>Aspergillus</i> antigen by use of a modified pretreatment procedure. <i>Journal of Clinical Microbiology</i> , 2008 , 46, 1391-7	9.7	18
91	High-dose meropenem in meningitis due to <i>Pseudomonas aeruginosa</i> . <i>Lancet, The</i> , 1992 , 339, 1117	4.0	18
90	The Fungal PCR Initiative's evaluation of in-house and commercial <i>Pneumocystis jirovecii</i> qPCR assays: Toward a standard for a diagnostics assay. <i>Medical Mycology</i> , 2020 , 58, 779-788	3.9	18
89	Galactomannan detection and diagnosis of invasive aspergillosis. <i>Clinical Infectious Diseases</i> , 2010 , 50, 1070-1; author reply 1071-2	11.6	17
88	<i>Aspergillus</i> tracheobronchitis after allogeneic bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2000 , 26, 1131-2	4.4	17
87	Comparison of Nonculture Blood-Based Tests for Diagnosing Invasive Aspergillosis in an Animal Model. <i>Journal of Clinical Microbiology</i> , 2016 , 54, 960-6	9.7	17
86	New Concepts in Diagnostics for Invasive Mycoses: Non-Culture-Based Methodologies. <i>Journal of Fungi (Basel, Switzerland)</i> , 2019 , 5,	5.6	16
85	Timely intervention for invasive fungal disease: should the road now lead to the laboratory instead of the pharmacy?. <i>Clinical Infectious Diseases</i> , 2009 , 48, 1052-4	11.6	16
84	Consensus definitions for invasive fungal disease: Strengths, limitations, and revisions. <i>Medical Mycology</i> , 2006 , 44, S285-S288	3.9	16
83	Deferasirox as adjunctive therapy for mucormycosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 519-20	5.1	15
82	Triggers for driving treatment of at-risk patients with invasive fungal disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68 Suppl 3, iii17-iii24	5.1	14
81	<i>Clostridium septicum</i> sepsis and neutropenic enterocolitis in a patient treated with intensive chemotherapy for acute myeloid leukemia. <i>Annals of Hematology</i> , 1997 , 74, 143-7	3	14
80	Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 60, 385-93	5.1	14
79	<i>Aspergillus</i> galactomannan antigen levels in allogeneic haematopoietic stem cell transplant recipients given total parenteral nutrition. <i>Transplant Infectious Disease</i> , 2002 , 4, 64-5	2.7	14

78	Aspergillus fumigatus pneumonia in neutropenic patients during therapy with fluconazole for infection due to Candida species. <i>Clinical Infectious Diseases</i> , 1993 , 16, 734-5	11.6	14
77	Incidence of and risk factors for persistent gram-positive bacteraemia and catheter-related thrombosis in haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2014 , 49, 264-9	4.4	13
76	EUCAST technical note on posaconazole. <i>Clinical Microbiology and Infection</i> , 2011 , 17, E16-7	9.5	13
75	Genetic variants and the risk for invasive mould disease in immunocompromised hematology patients. <i>Current Opinion in Infectious Diseases</i> , 2011 , 24, 554-63	5.4	13
74	Halo sign and improved outcome. <i>Clinical Infectious Diseases</i> , 2007 , 44, 1666-7; author reply 1667-8	11.6	13
73	Assessment and reporting of clinical trials of empirical therapy in neutropenic patients. <i>Journal of Antimicrobial Chemotherapy</i> , 1991 , 27, 377-87	5.1	13
72	Ceftazidime alone for treating Pseudomonas aeruginosa septicaemia in neutropenic patients. <i>Journal of Infection</i> , 1986 , 13, 125-31	18.9	13
71	Protective environment for hematopoietic cell transplant (HSCT) recipients: The Infectious Diseases Working Party EBMT analysis of global recommendations on health-care facilities. <i>Bone Marrow Transplantation</i> , 2018 , 53, 1131-1138	4.4	12
70	Ceftazidime with or without amikacin for the empiric treatment of localized infections in febrile, granulocytopenic patients. <i>Annals of Hematology</i> , 1991 , 63, 195-200	3	12
69	Long-term health related quality of life following intensive care during treatment for haematological malignancies. <i>PLoS ONE</i> , 2014 , 9, e87779	3.7	12
68	The potential role of lactoferrin and derivatives in the management of infectious and inflammatory complications of hematology patients receiving a hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2008 , 10, 80-9	2.7	11
67	Issues in antifungal stewardship: an opportunity that should not be lost. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 969-974	5.1	11
66	Interlaboratory evaluation of Mucorales PCR assays for testing serum specimens: A study by the fungal PCR Initiative and the Modimucor study group. <i>Medical Mycology</i> , 2021 , 59, 126-138	3.9	11
65	Impact of palifermin on intestinal mucositis of HSCT recipients after BEAM. <i>Bone Marrow Transplantation</i> , 2014 , 49, 8-10	4.4	10
64	A review of quality assessment of the methodology used in guidelines and systematic reviews on oral mucositis. <i>Journal of Clinical Nursing</i> , 2009 , 18, 3-12	3.2	10
63	Providing oral care in haematological oncology patients: nurses' knowledge and skills. <i>European Journal of Oncology Nursing</i> , 2008 , 12, 291-8	2.8	10
62	Validating PCR for detecting invasive aspergillosis. <i>British Journal of Haematology</i> , 2004 , 127, 235-6	4.5	10
61	Empiric treatment of localized infections in the febrile neutropenic patient with monotherapy. <i>Leukemia and Lymphoma</i> , 1993 , 9, 193-203	1.9	10

60	Standardization of Aspergillus PCR diagnosis. <i>Bone Marrow Transplantation</i> , 2012 , 47, 299-300	4.4	9
59	Monitoring cyclosporine using blood drawn via a central venous catheter. <i>Bone Marrow Transplantation</i> , 2003 , 32, 1037	4.4	9
58	High-dose itraconazole for the treatment of cerebral aspergillosis. <i>Clinical Infectious Diseases</i> , 1996 , 23, 1196-7	11.6	9
57	Describing and comparing in-vitro antimicrobial activity by the box-plot technique. <i>Journal of Antimicrobial Chemotherapy</i> , 1992 , 30, 713-9	5.1	9
56	Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people. <i>The Cochrane Library</i> , 2019 , 9, CD009551	5.2	9
55	Towards individually tailored empiric antibiotic therapy in febrile granulocytopenic patients. <i>Netherlands Journal of Medicine</i> , 1990 , 37, 111-9	0.5	8
54	Allogeneic bone marrow transplantation after partial lobectomy for aspergillosis of the lung. <i>Bone Marrow Transplantation</i> , 1988 , 3, 509-12	4.4	8
53	Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients-authorsTresponse. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 1266-1268	5.1	7
52	How prompt is prompt in daily practice? Earlier initiation of empirical antibacterial therapy for the febrile neutropenic patient. <i>European Journal of Cancer Care</i> , 2011 , 20, 679-85	2.4	7
51	Association of fluconazole pharmacodynamics with mortality in patients with candidemia. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 2704-5; author reply 2705-6	5.9	7
50	Continuous non-invasive monitoring of the skin temperature of HSCT recipients. <i>Supportive Care in Cancer</i> , 2010 , 18, 37-42	3.9	7
49	Infection in the neutropenic and haematopoietic stem cell transplant recipient. <i>Current Opinion in Infectious Diseases</i> , 2000 , 13, 337-342	5.4	7
48	Host impairments in patients with neoplastic diseases. <i>Cancer Treatment and Research</i> , 2014 , 161, 1-41	3.5	7
47	Chemoprophylaxis for the prevention of bacterial and fungal infections. <i>Cancer Treatment and Research</i> , 1995 , 79, 45-81	3.5	7
46	Nucleic Acid Tools for Invasive Fungal Disease Diagnosis. <i>Current Fungal Infection Reports</i> , 2020 , 14, 76-88	4.4	6
45	Differences in T cell depletion and intestinal mucositis explain inconsistent effects of NOD2/CARD15 polymorphisms in SCT. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1421-3	4.7	6
44	Evolution of the clinical manifestations of infection during the course of febrile neutropenia in patients with malignancy. <i>Infection</i> , 1998 , 26, 349-54	5.8	6
43	Determining mucosal barrier injury to the oesophagus using CT scan. <i>Supportive Care in Cancer</i> , 2007 , 15, 1105-8	3.9	6

42	Symptoms and diagnosis of nosocomial fungal infections -- state-of-the-art. <i>European Journal of Medical Research</i> , 2002 , 7, 192-9	4.8	6
41	Lymphocyte subsets, granulocyte-colony-stimulating factor responsiveness and post-stem cell transplantation infections: mucositis is the underestimated confounder?. <i>Cytotherapy</i> , 2012 , 14, 381-3	4.8	5
40	Can We Achieve Clinical Breakpoints for the Triazoles in Aspergillosis?. <i>Current Fungal Infection Reports</i> , 2011 , 5, 128-134	1.4	5
39	Issues in genetic association studies: limitations of statistical analysis and biological plausibility. <i>Bone Marrow Transplantation</i> , 2011 , 46, 906-7	4.4	5
38	Treatment of fungal infections in surgical patients using conventional antifungals. <i>Journal of Chemotherapy</i> , 1999 , 11, 494-503	2.3	5
37	Bacteraemia caused by <i>Stomatococcus mucilaginosus</i> in a granulocytopenic patient with acute lymphocytic leukaemia. <i>Netherlands Journal of Medicine</i> , 1989 , 35, 143-6	0.5	5
36	When to change treatment of acute invasive aspergillosis: an expert viewpoint. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 ,	5.1	5
35	Towards a standard for Aspergillus PCR - requirements, process and results. <i>Infectio</i> , 2012 , 16, 64-72	0.7	4
34	The end of the road for empirical antifungal treatment?. <i>Lancet Infectious Diseases, The</i> , 2013 , 13, 470-2	25.5	4
33	Host-microbe interactions in stem cell transplantation: recognizing <i>Candida</i> in infection and inflammation. <i>Virulence</i> , 2010 , 1, 180-4	4.7	4
32	Controversies in the antibacterial treatment of patients with neutropenia: a matter of comprehension or apprehension?. <i>Cancer Investigation</i> , 1997 , 15, 37-46	2.1	4
31	A strategy for managing fungal infections in haematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2000 , 2, 88-95	2.7	4
30	European Surveillance of Infections in Cancer Patients--ESIC. <i>Chemotherapy</i> , 1999 , 45, 237-41	3.2	4
29	European surveillance of infections and risk factors in cancer patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1999 , 18, 161-3	5.3	4
28	Mucosal Barrier Injury and Infections 2011 , 167-173		4
27	Comment on: T2Candida MR as a predictor of outcome in patients with suspected invasive candidiasis starting empirical antifungal treatment: a prospective pilot study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 532-533	5.1	3
26	Infections in the Immunocompromised Host 2015 , 3384-3394.e2		3
25	Reply to Miceli and Anaissie. <i>Clinical Infectious Diseases</i> , 2007 , 44, 760-761	11.6	3

24	Febrile neutropenia: antifungal prophylaxis. <i>International Journal of Antimicrobial Agents</i> , 2000 , 16, 127-30.3	3
23	Bacteraemia and Hickman catheters. <i>Lancet, The</i> , 1985 , 2, 48	40 3
22	The impact of anti-mould prophylaxis on Aspergillus PCR blood testing for the diagnosis of invasive aspergillosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 635-638	5.1 3
21	Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. <i>Clinical Infectious Diseases</i> , 2006 , 43, 1031-9	11.6 2
20	Commentary on the MAFF technical report: a review of antimicrobial resistance in the food chain. Ministry of Agriculture Fisheries and Food. <i>International Journal of Antimicrobial Agents</i> , 1999 , 12, 63-5	14.3 2
19	Reply to Mafaciolli and Pasqualotto. <i>Clinical Infectious Diseases</i> , 2020 , 71, 2542-2543	11.6 1
18	A multidisciplinary approach to managing invasive fungal disease. Introduction and aims. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68 Suppl 3, iii3-4	5.1 1
17	Care pathways for managing invasive mould diseases. <i>International Journal of Antimicrobial Agents</i> , 2013 , 42, 5-9	14.3 1
16	Introduction and aims. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, i3-i4	5.1 1
15	Challenges and progress in setting a standard for PCR for invasive aspergillosis. <i>Current Fungal Infection Reports</i> , 2008 , 2, 232-236	1.4 1
14	Limitations of box-plots in summarizing MIC data. <i>Journal of Antimicrobial Chemotherapy</i> , 1994 , 33, 1251-2	1
13	Infection Prevention [Protected Environment and Infection Control 2011 , 541-550	1
12	An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy 1995 , 70, 83	1
11	Using routine blood parameters to anticipate clinical outcomes in invasive aspergillosis. <i>Clinical Microbiology and Infection</i> , 2020 , 26, 781.e1-781.e8	9.5 1
10	The Evidence Supporting the Revised EORTC/MSGERC Definitions for Invasive Fungal Infections. <i>Clinical Infectious Diseases</i> , 2021 , 72, S77-S78	11.6 1
9	Reply to Herbrecht et al. <i>Clinical Infectious Diseases</i> , 2020 , 71, 2774-2775	11.6
8	Three major achievements of the Infections Disease Group. <i>European Journal of Cancer, Supplement</i> , 2012 , 10, 88-93	1.6
7	Regional Variations in the Further Management of Neutropenic Patients already Receiving Empirical Antimicrobial Therapy. <i>Hematology</i> , 2001 , 5, 413-20	2.2

- 6 Comparison of methods for the interpretation of disk diffusion susceptibility tests for augmentin. *Diagnostic Microbiology and Infectious Disease*, **1986**, 5, 255-63 2.9
- 5 Host impairments in patients with neoplastic diseases. *Cancer Treatment and Research*, **1998**, 96, 1-32 3.5
- 4 Defining Invasive Aspergillosis: What the Revised EORTC/MSG Definitions Have in Store **2009**, 423-435
- 3 Supportive Care in the Management of Leukaemia 463-482
- 2 Reply to Luppi et al. *Clinical Infectious Diseases*, **2020**, 71, 3266 11.6
- 1 Supportive Care in the Management of Leukaemia 586-602